Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma

Journal of Cardiothoracic Surgery

Volumn 8, Issue 1, 2013, Pages

  Zhang, Zhenfa ^a   Wang, Anlei ^a   Sun, Bingsheng ^a   Zhan, Zhongli ^a   Chen, Kexin ^a   Wang, Changli ^a  

^a Lung Tumor Department of the Affiliated Cancer Hospital of Tian Jin Medical University   (China)

Author keywords

Claudin 1; Claudin10; Invasive lepidic predominant adenocarcinoma; Lung adenocarcinoma in situ

Indexed keywords

EID: 84876077448     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/1749-8090-8-95     Document Type: Article

References (31)

1. Liebow AA. Bronchiolo-alveolar carcinoma. Adv Intern Med 1960, 10:329-358.
2. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. WHO Classification of Tumors: Pathology and Genetics of tumors of the Lung,Pleura, Thymus and Heart 2004, 35-44. Lyon: IARC Press.
3. Travis WD, Brambilla E, Noguchi M. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society, International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011, 6:244-285. 10.1097/JTO.0b013e318206a221, 21252716.
4. Soh J, Toyooka S, Ichihara S, Asano H, Kobayashi N, Suehisa H, Otani H, Ymamoto H, Ichimura K, Kiura K, Gazdar AF, Date H. Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Thorac Oncol 2008, 3:340-347. 10.1097/JTO.0b013e318168d20a, 2758162, 18379350.
5. Raz DJ, He B, Rosell R, Jablons DM. Bronchioloalveolar carcinoma: a review. Clin Lung Cancer 2006, 7:313-322. 10.3816/CLC.2006.n.012, 16640802.
6. Terasaki H, Niki T, Matsuno Y, Yamada T, Maeshima A, Asamura H, Hayabuchi N, Hirohashi S. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol 2003, 27:937-51. 10.1097/00000478-200307000-00009, 12826886.
7. Sakuragi T, Sakao Y, Fujita H. Lymph node metastasis, recurrence, and prognosis in small peripheral lung adenocarcinoma: analysis based on replacement. Jpn J Thorac Cardiovasc Surg 2002, 50:424-9. 10.1007/BF02913176, 12428382.
8. Kondo D, Yamada K, Kitayama Y, Hoshi S. Peripheral lung adenocarcinomas: 10 mm or less in diameter. Ann Thorac Surg 2003, 76:350-5. 10.1016/S0003-4975(03)00340-0, 12902062.
9. Makimoto Y, Nabeshima K, Iwasaki H, Miyoshi T, Enatsu S, Shiraishi T, Iwasaki A, Shirakusa T, Kikuchi M. Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (<=20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours). Histopathology 2005, 46:677-84. 10.1111/j.1365-2559.2005.02126.x, 15910599.
10. Jiang R, Jin Z, Liu Z, Sun L, Wang L, Li K. Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. Mol Diagn Ther 2011, 15:347-352. 10.1007/BF03256470, 22208386.
11. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193. 10.1093/bioinformatics/19.2.185, 12538238.
12. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, Liu CC, Singh S, Chen WJ, Chen JJ, Yang PC. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007, 356:11-20. 10.1056/NEJMoa060096, 17202451.
13. Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K, Wheeler J, Gleave M, Sanghera J, Dedhar S. Regulationof tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 2004, 5:79-90. 10.1016/S1535-6108(03)00281-2, 14749128.
14. Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003, 22:2021-2033. 10.1038/sj.onc.1206199, 12673207.
15. Usami Y, Chiba H, Nakayama F. Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus. Hum Pathol 2006, 37:569-577. 10.1016/j.humpath.2005.12.018, 16647955.
16. Sauer T, Pedersen MK, Ebeltoft K, Næss O. Reducedexpression of Claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease. Cytopathology 2005, 16:193-198. 10.1111/j.1365-2303.2005.00257.x, 16048505.
17. Michl P, Barth C, Buchholz M, Lerch MM, Rolke M, Holzmann KH, Menke A, Fensterer H, Giehl K, Löhr M, Leder G, Iwamura T, Adler G, Gress TM. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res 2003, 63:6265-6271.
18. Rangel LB, Agarwal R, D'Souza T, Pizer ES, Alò PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, Morin PJ. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 2003, 9:2567-2575.
19. Soini Y. Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology 2005, 46:551-560. 10.1111/j.1365-2559.2005.02127.x, 15842637.
20. Lee JW, Lee SJ, Seo J, Song SY, Ahn G, Park CS, Lee JH, Kim BG, Bae DS. Increased expressions of claudin-1 and claudin-7 during the progression of cervical neoplasia. Gynecol Oncol 2005, 97:53-59. 10.1016/j.ygyno.2004.11.058, 15790437.
21. Agarwal R, D'Souza T, Morin PJ. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res 2005, 65:7378-7385. 10.1158/0008-5472.CAN-05-1036, 16103090.
22. Chao YC, Pan SH, Yang SC, Yu SL, Che TF, Lin CW, Tsai MS, Chang GC, Wu CH, Wu YY, Lee YC, Hong TM, Yang PC. Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med 2009, 179:123-133. 10.1164/rccm.200803-456OC, 18787218.
23. Dhawan P, Singh AB, Deane NG. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 2005, 115:1765-1776. 10.1172/JCI24543, 1150288, 15965503.
24. Escudero-Esparza A, Jiang WG, Martin TA. The Claudin family and its role in cancer and metastasis. Front Biosci 2011, 16:1069-1083. Publisher: Tampa, Fla. United States, 10.2741/3736, 21196219.
25. Jin T, George Fantus I, Sun J. Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of β-catenin. Cell Signal 2008, 20:1697-1704. 10.1016/j.cellsig.2008.04.014, 18555664.
26. Miwa N, Furuse M, Tsukita S, Niikawa N, Nakamura Y, Furukawa Y. Involvement of claudin-1 in the β-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. Oncol Res 2000, 12:469-476.
27. Mankertz J, Hillenbrand B, Tavalali S, Huber O, Fromm M, Schulzke JD. Functional crosstalk between Wnt signaling and Cdx-related transcriptional activation in the regulation of the claudin-2 promoter activity. Biochem Biophys Res Commun 2004, 314:1001-1007. 10.1016/j.bbrc.2003.12.185, 14751232.
28. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 2005, 208:126-140. 10.1111/j.0105-2896.2005.00332.x, 16313345.
29. Preston GA, Lyon TT, Yin Y. Induction of apoptosis by c-Fos protein. Mol Cell Biol 1996, 16:211-218. 230994, 8524298.
30. Overall CM, Kleifeld O. Validating matrix metalloproteinases as drug targets and anti-cancer targets for cancer therapy. Nat Rev Cancer 2006, 6:227-238. 10.1038/nrc1821, 16498445.
31. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol 2008, 214:283-293. 10.1002/path.2282, 18095256.